418 related articles for article (PubMed ID: 29857542)
21. Role of glycosylation on the ensemble of conformations in the MUC1 immunodominant epitope.
Singh J; Her C; Supekar N; Boons GJ; Krishnan VV; Brooks CL
J Pept Sci; 2020 Jan; 26(1):e3229. PubMed ID: 31729101
[TBL] [Abstract][Full Text] [Related]
22. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
23. Functional neoglycopeptides: synthesis and characterization of a new class of MUC1 glycoprotein models having core 2-based O-glycan and complex-type N-glycan chains.
Matsushita T; Sadamoto R; Ohyabu N; Nakata H; Fumoto M; Fujitani N; Takegawa Y; Sakamoto T; Kurogochi M; Hinou H; Shimizu H; Ito T; Naruchi K; Togame H; Takemoto H; Kondo H; Nishimura S
Biochemistry; 2009 Nov; 48(46):11117-33. PubMed ID: 19852465
[TBL] [Abstract][Full Text] [Related]
24. Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine.
Hanisch FG; Ninkovic T
Curr Protein Pept Sci; 2006 Aug; 7(4):307-15. PubMed ID: 16918445
[TBL] [Abstract][Full Text] [Related]
25. A straightforward protocol for the preparation of high performance microarray displaying synthetic MUC1 glycopeptides.
Matsushita T; Takada W; Igarashi K; Naruchi K; Miyoshi R; Garcia-Martin F; Amano M; Hinou H; Nishimura S
Biochim Biophys Acta; 2014 Mar; 1840(3):1105-16. PubMed ID: 24246952
[TBL] [Abstract][Full Text] [Related]
26. Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice.
Wu X; Yin Z; McKay C; Pett C; Yu J; Schorlemer M; Gohl T; Sungsuwan S; Ramadan S; Baniel C; Allmon A; Das R; Westerlind U; Finn MG; Huang X
J Am Chem Soc; 2018 Dec; 140(48):16596-16609. PubMed ID: 30398345
[TBL] [Abstract][Full Text] [Related]
27. Tumor-associated MUC1 tandem-repeat glycopeptide microarrays to evaluate serum- and monoclonal-antibody specificity.
Westerlind U; Schröder H; Hobel A; Gaidzik N; Kaiser A; Niemeyer CM; Schmitt E; Waldmann H; Kunz H
Angew Chem Int Ed Engl; 2009; 48(44):8263-7. PubMed ID: 19718733
[No Abstract] [Full Text] [Related]
28. Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes.
Ninkovic T; Kinarsky L; Engelmann K; Pisarev V; Sherman S; Finn OJ; Hanisch FG
Mol Immunol; 2009 Nov; 47(1):131-40. PubMed ID: 19007994
[TBL] [Abstract][Full Text] [Related]
29. Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy.
Madsen CB; Wandall HH; Pedersen AE
Immunopharmacol Immunotoxicol; 2013 Dec; 35(6):649-52. PubMed ID: 24063621
[TBL] [Abstract][Full Text] [Related]
30. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
[TBL] [Abstract][Full Text] [Related]
31. Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity.
Irimura T; Denda K; Iida Si; Takeuchi H; Kato K
J Biochem; 1999 Dec; 126(6):975-85. PubMed ID: 10578046
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.
Sarkar S; Salyer AC; Wall KA; Sucheck SJ
Bioconjug Chem; 2013 Mar; 24(3):363-75. PubMed ID: 23444835
[TBL] [Abstract][Full Text] [Related]
33. The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialyl alpha 2-3galactosyl beta 1-3N-acetylgalactosaminide linked to a distinct threonine residue in the MUC1 tandem repeat.
Takeuchi H; Kato K; Denda-Nagai K; Hanisch FG; Clausen H; Irimura T
J Immunol Methods; 2002 Dec; 270(2):199-209. PubMed ID: 12379325
[TBL] [Abstract][Full Text] [Related]
34. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR
Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660
[TBL] [Abstract][Full Text] [Related]
35. Design of a MUC1-based cancer vaccine.
Hanisch FG
Biochem Soc Trans; 2005 Aug; 33(Pt 4):705-8. PubMed ID: 16042579
[TBL] [Abstract][Full Text] [Related]
36. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
[TBL] [Abstract][Full Text] [Related]
37. Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996.
Price MR; Rye PD; Petrakou E; Murray A; Brady K; Imai S; Haga S; Kiyozuka Y; Schol D; Meulenbroek MF; Snijdewint FG; von Mensdorff-Pouilly S; Verstraeten RA; Kenemans P; Blockzjil A; Nilsson K; Nilsson O; Reddish M; Suresh MR; Koganty RR; Fortier S; Baronic L; Berg A; Longenecker MB; Hilgers J
Tumour Biol; 1998; 19 Suppl 1():1-20. PubMed ID: 9422084
[TBL] [Abstract][Full Text] [Related]
38. Nuclear magnetic resonance-based dissection of a glycosyltransferase specificity for the mucin MUC1 tandem repeat.
Brokx RD; Revers L; Zhang Q; Yang S; Mal TK; Ikura M; Gariépy J
Biochemistry; 2003 Dec; 42(47):13817-25. PubMed ID: 14636048
[TBL] [Abstract][Full Text] [Related]
39. Localization of O-glycosylation sites on glycopeptide fragments from lactation-associated MUC1. All putative sites within the tandem repeat are glycosylation targets in vivo.
Müller S; Goletz S; Packer N; Gooley A; Lawson AM; Hanisch FG
J Biol Chem; 1997 Oct; 272(40):24780-93. PubMed ID: 9312074
[TBL] [Abstract][Full Text] [Related]
40. Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid.
Stergiou N; Gaidzik N; Heimes AS; Dietzen S; Besenius P; Jäkel J; Brenner W; Schmidt M; Kunz H; Schmitt E
Cancer Immunol Res; 2019 Jan; 7(1):113-122. PubMed ID: 30413430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
